OM
KTTA icon

Opaleye Management’s Pasithea Therapeutics KTTA Stock Holding History

Opaleye Management’s Portfolio KTTA Stock Details KTTA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.06M Buy
+2,050,000
New +$1.41M 0.1% 54

Other funds holding KTTA

CCC
Cable Car Capital San Francisco, California $4.66B AUM 77.16% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $177M AUM 91.13% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return
SCM
Squadron Capital Management Westmont, Illinois $322M AUM
AI
AdvisorShares Investments Bethesda, Maryland $828M AUM 37.72% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
PAP
Persistent Asset Partners Hong Kong $335M AUM 275.57% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Opaleye Management's KTTA Position: Q2 2026 in Review

Opaleye Management opened a new position in Pasithea Therapeutics (KTTA) in Q2 2026: 2,050,000 shares worth $1.06M. The stake represents 0.1% of the portfolio and ranks #54 among its holdings.

25 funds tracked by Wall St. Rank hold KTTA as of Q2 2026.

  • Opaleye Management held 2,050,000 shares of Pasithea Therapeutics worth $1.06M as of Q2 2026.
  • Pasithea Therapeutics was a new Opaleye Management position in Q2 2026.
  • Pasithea Therapeutics made up 0.1% of Opaleye Management's portfolio in Q2 2026, its #54 holding.
  • 25 funds tracked by Wall St. Rank held Pasithea Therapeutics as of Q2 2026.

Based on Opaleye Management's 13F filing for Q2 2026, filed 14 Aug 2026.